+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Global Angioedema Treatment Market by Drugs Type (C1 Esterase Inhibitor, Kallikrein Inhibitor, Selective Bradykinin B2 Receptor Antagonist), Route of Administration (Injections, Oral), End-User - Forecast 2024-2030

  • PDF Icon

    Report

  • 183 Pages
  • January 2024
  • Region: Global
  • 360iResearch™
  • ID: 4904682
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Angioedema Treatment Market size was estimated at USD 4.69 billion in 2023, USD 5.50 billion in 2024, and is expected to grow at a CAGR of 17.28% to reach USD 14.32 billion by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Angioedema Treatment Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Angioedema Treatment Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Angioedema Treatment Market, highlighting leading vendors and their innovative profiles. These include Adverum Biotechnologies, Inc., AMBOSS GmbH, Apotex Corp., Attune Pharmaceuticals, Inc., BioCryst Pharmaceuticals, Inc., Cipla USA Inc., CSL Behring GmbH, Fresenius Kabi USA, LLC, Ionis Pharmaceuticals, Inc., KalVista Pharmaceuticals, Inc., Lecturio GmbH, Merck & Co., Inc., Pharming Group N.V., Sanofi-Aventis Groupe S.A., Slayback Pharma LLC, Takeda Pharmaceutical Company Limited, and Viropharma Biologics LLC.

Market Segmentation & Coverage

This research report categorizes the Angioedema Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Drugs Type
    • C1 Esterase Inhibitor
      • Berinert
      • Cinryze
      • Haegarda
      • Ruconest
    • Kallikrein Inhibitor
      • Kalbitor
    • Selective Bradykinin B2 Receptor Antagonist
      • Firazyr
  • Route of Administration
    • Injections
    • Oral
  • End-User
    • Clinics
    • Hospitals
    • Research Organizations
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects

  1. Market Penetration: It presents comprehensive information on the market provided by key players.
  2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
  3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
  4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
  5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as

  1. What is the market size and forecast of the Angioedema Treatment Market?
  2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Angioedema Treatment Market?
  3. What are the technology trends and regulatory frameworks in the Angioedema Treatment Market?
  4. What is the market share of the leading vendors in the Angioedema Treatment Market?
  5. Which modes and strategic moves are suitable for entering the Angioedema Treatment Market?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.

This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.

Frequently Asked Questions about the Global Angioedema Treatment Market

What is the estimated value of the Global Angioedema Treatment Market?

The Global Angioedema Treatment Market was estimated to be valued at $5.5 Billion in 2024.

What is the growth rate of the Global Angioedema Treatment Market?

The growth rate of the Global Angioedema Treatment Market is 17.2%, with an estimated value of $14.32 Billion by 2030.

What is the forecasted size of the Global Angioedema Treatment Market?

The Global Angioedema Treatment Market is estimated to be worth $14.32 Billion by 2030.

Who are the key companies in the Global Angioedema Treatment Market?

Key companies in the Global Angioedema Treatment Market include Adverum Biotechnologies, Inc., AMBOSS GmbH, Apotex Corp., Attune Pharmaceuticals, Inc., BioCryst Pharmaceuticals, Inc., Cipla USA Inc., CSL Behring GmbH, Fresenius Kabi USA, LLC, Ionis Pharmaceuticals, Inc. and KalVista Pharmaceuticals, Inc..

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Angioedema Treatment Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing cases of hereditary angioedema (HAE)
5.1.1.2. Growing initiatives for improving awareness levels among the population
5.1.1.3. Rising incidence of disease-related genetic mutations
5.1.2. Restraints
5.1.2.1. Misdiagnosis of angioedema
5.1.3. Opportunities
5.1.3.1. Government initiatives to facilitate faster diagnosis and provide optimal standards of treatment
5.1.3.2. Development of advance therapeutics for hereditary angioedema disorders treatment
5.1.4. Challenges
5.1.4.1. High cost of the drugs used for treatment
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Angioedema Treatment Market, by Drugs Type
6.1. Introduction
6.2. C1 Esterase Inhibitor
6.3.1. Berinert
6.3.2. Cinryze
6.3.3. Haegarda
6.3.4. Ruconest
6.3. Kallikrein Inhibitor
6.4.1. Kalbitor
6.4. Selective Bradykinin B2 Receptor Antagonist
6.5.1. Firazyr
7. Angioedema Treatment Market, by Route of Administration
7.1. Introduction
7.2. Injections
7.3. Oral
8. Angioedema Treatment Market, by End-User
8.1. Introduction
8.2. Clinics
8.3. Hospitals
8.4. Research Organizations
9. Americas Angioedema Treatment Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Angioedema Treatment Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Angioedema Treatment Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.2. Market Share Analysis, By Key Player
12.3. Competitive Scenario Analysis, By Key Player
13. Competitive Portfolio
13.1. Key Company Profiles
13.1.1. Adverum Biotechnologies, Inc.
13.1.2. AMBOSS GmbH
13.1.3. Apotex Corp.
13.1.4. Attune Pharmaceuticals, Inc.
13.1.5. BioCryst Pharmaceuticals, Inc.
13.1.6. Cipla USA Inc.
13.1.7. CSL Behring GmbH
13.1.8. Fresenius Kabi USA, LLC
13.1.9. Ionis Pharmaceuticals, Inc.
13.1.10. KalVista Pharmaceuticals, Inc.
13.1.11. Lecturio GmbH
13.1.12. Merck & Co., Inc.
13.1.13. Pharming Group N.V.
13.1.14. Sanofi-Aventis Groupe S.A.
13.1.15. Slayback Pharma LLC
13.1.16. Takeda Pharmaceutical Company Limited
13.1.17. Viropharma Biologics LLC
13.2. Key Product Portfolio
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing
List of Figures
FIGURE 1. ANGIOEDEMA TREATMENT MARKET RESEARCH PROCESS
FIGURE 2. ANGIOEDEMA TREATMENT MARKET SIZE, 2023 VS 2030
FIGURE 3. ANGIOEDEMA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. ANGIOEDEMA TREATMENT MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. ANGIOEDEMA TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. ANGIOEDEMA TREATMENT MARKET DYNAMICS
FIGURE 7. ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2023 VS 2030 (%)
FIGURE 8. ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
FIGURE 10. ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
FIGURE 12. ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS ANGIOEDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 14. AMERICAS ANGIOEDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES ANGIOEDEMA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 16. UNITED STATES ANGIOEDEMA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. ASIA-PACIFIC ANGIOEDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. ASIA-PACIFIC ANGIOEDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ANGIOEDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ANGIOEDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. ANGIOEDEMA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 22. ANGIOEDEMA TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
List of Tables
TABLE 1. ANGIOEDEMA TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. ANGIOEDEMA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 6. ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 7. ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 8. ANGIOEDEMA TREATMENT MARKET SIZE, BY BERINERT, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. ANGIOEDEMA TREATMENT MARKET SIZE, BY CINRYZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. ANGIOEDEMA TREATMENT MARKET SIZE, BY HAEGARDA, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. ANGIOEDEMA TREATMENT MARKET SIZE, BY RUCONEST, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
TABLE 14. ANGIOEDEMA TREATMENT MARKET SIZE, BY KALBITOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
TABLE 17. ANGIOEDEMA TREATMENT MARKET SIZE, BY FIRAZYR, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 19. ANGIOEDEMA TREATMENT MARKET SIZE, BY INJECTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. ANGIOEDEMA TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 22. ANGIOEDEMA TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. ANGIOEDEMA TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. ANGIOEDEMA TREATMENT MARKET SIZE, BY RESEARCH ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. AMERICAS ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 26. AMERICAS ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 27. AMERICAS ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
TABLE 28. AMERICAS ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
TABLE 29. AMERICAS ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 30. AMERICAS ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 31. AMERICAS ANGIOEDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 32. ARGENTINA ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 33. ARGENTINA ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 34. ARGENTINA ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
TABLE 35. ARGENTINA ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
TABLE 36. ARGENTINA ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 37. ARGENTINA ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 38. BRAZIL ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 39. BRAZIL ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 40. BRAZIL ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
TABLE 41. BRAZIL ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
TABLE 42. BRAZIL ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 43. BRAZIL ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 44. CANADA ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 45. CANADA ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 46. CANADA ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
TABLE 47. CANADA ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
TABLE 48. CANADA ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 49. CANADA ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 50. MEXICO ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 51. MEXICO ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 52. MEXICO ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
TABLE 53. MEXICO ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
TABLE 54. MEXICO ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 55. MEXICO ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 56. UNITED STATES ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 57. UNITED STATES ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 58. UNITED STATES ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
TABLE 59. UNITED STATES ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
TABLE 60. UNITED STATES ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 61. UNITED STATES ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 62. UNITED STATES ANGIOEDEMA TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 63. ASIA-PACIFIC ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 64. ASIA-PACIFIC ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 65. ASIA-PACIFIC ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
TABLE 66. ASIA-PACIFIC ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
TABLE 67. ASIA-PACIFIC ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 68. ASIA-PACIFIC ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 69. ASIA-PACIFIC ANGIOEDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 70. AUSTRALIA ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 71. AUSTRALIA ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 72. AUSTRALIA ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
TABLE 73. AUSTRALIA ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
TABLE 74. AUSTRALIA ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 75. AUSTRALIA ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 76. CHINA ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 77. CHINA ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 78. CHINA ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
TABLE 79. CHINA ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
TABLE 80. CHINA ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 81. CHINA ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 82. INDIA ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 83. INDIA ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 84. INDIA ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
TABLE 85. INDIA ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
TABLE 86. INDIA ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 87. INDIA ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 88. INDONESIA ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 89. INDONESIA ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 90. INDONESIA ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
TABLE 91. INDONESIA ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
TABLE 92. INDONESIA ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 93. INDONESIA ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 94. JAPAN ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 95. JAPAN ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 96. JAPAN ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
TABLE 97. JAPAN ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
TABLE 98. JAPAN ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 99. JAPAN ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 100. MALAYSIA ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 101. MALAYSIA ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 102. MALAYSIA ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
TABLE 103. MALAYSIA ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
TABLE 104. MALAYSIA ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 105. MALAYSIA ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 106. PHILIPPINES ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 107. PHILIPPINES ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 108. PHILIPPINES ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
TABLE 109. PHILIPPINES ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
TABLE 110. PHILIPPINES ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 111. PHILIPPINES ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 112. SINGAPORE ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 113. SINGAPORE ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 114. SINGAPORE ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
TABLE 115. SINGAPORE ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
TABLE 116. SINGAPORE ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 117. SINGAPORE ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 118. SOUTH KOREA ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 119. SOUTH KOREA ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 120. SOUTH KOREA ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
TABLE 121. SOUTH KOREA ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
TABLE 122. SOUTH KOREA ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 123. SOUTH KOREA ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 124. TAIWAN ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 125. TAIWAN ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 126. TAIWAN ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
TABLE 127. TAIWAN ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
TABLE 128. TAIWAN ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 129. TAIWAN ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 130. THAILAND ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 131. THAILAND ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 132. THAILAND ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
TABLE 133. THAILAND ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
TABLE 134. THAILAND ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 135. THAILAND ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 136. VIETNAM ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 137. VIETNAM ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 138. VIETNAM ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
TABLE 139. VIETNAM ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
TABLE 140. VIETNAM ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 141. VIETNAM ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 142. EUROPE, MIDDLE EAST & AFRICA ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 143. EUROPE, MIDDLE EAST & AFRICA ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 144. EUROPE, MIDDLE EAST & AFRICA ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
TABLE 145. EUROPE, MIDDLE EAST & AFRICA ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
TABLE 146. EUROPE, MIDDLE EAST & AFRICA ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 147. EUROPE, MIDDLE EAST & AFRICA ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 148. EUROPE, MIDDLE EAST & AFRICA ANGIOEDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 149. DENMARK ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 150. DENMARK ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 151. DENMARK ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
TABLE 152. DENMARK ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
TABLE 153. DENMARK ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 154. DENMARK ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 155. EGYPT ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 156. EGYPT ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 157. EGYPT ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
TABLE 158. EGYPT ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
TABLE 159. EGYPT ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 160. EGYPT ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 161. FINLAND ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 162. FINLAND ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 163. FINLAND ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
TABLE 164. FINLAND ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
TABLE 165. FINLAND ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 166. FINLAND ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 167. FRANCE ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 168. FRANCE ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 169. FRANCE ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
TABLE 170. FRANCE ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
TABLE 171. FRANCE ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 172. FRANCE ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 173. GERMANY ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 174. GERMANY ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 175. GERMANY ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
TABLE 176. GERMANY ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
TABLE 177. GERMANY ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 178. GERMANY ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 179. ISRAEL ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 180. ISRAEL ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 181. ISRAEL ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
TABLE 182. ISRAEL ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
TABLE 183. ISRAEL ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 184. ISRAEL ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 185. ITALY ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 186. ITALY ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 187. ITALY ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
TABLE 188. ITALY ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
TABLE 189. ITALY ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 190. ITALY ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 191. NETHERLANDS ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 192. NETHERLANDS ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 193. NETHERLANDS ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
TABLE 194. NETHERLANDS ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
TABLE 195. NETHERLANDS ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 196. NETHERLANDS ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 197. NIGERIA ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 198. NIGERIA ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 199. NIGERIA ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
TABLE 200. NIGERIA ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
TABLE 201. NIGERIA ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 202. NIGERIA ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 203. NORWAY ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 204. NORWAY ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 205. NORWAY ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
TABLE 206. NORWAY ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
TABLE 207. NORWAY ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 208. NORWAY ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 209. POLAND ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 210. POLAND ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 211. POLAND ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
TABLE 212. POLAND ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
TABLE 213. POLAND ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 214. POLAND ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 215. QATAR ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 216. QATAR ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 217. QATAR ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
TABLE 218. QATAR ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
TABLE 219. QATAR ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 220. QATAR ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 221. RUSSIA ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 222. RUSSIA ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 223. RUSSIA ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
TABLE 224. RUSSIA ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
TABLE 225. RUSSIA ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 226. RUSSIA ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 227. SAUDI ARABIA ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 228. SAUDI ARABIA ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 229. SAUDI ARABIA ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
TABLE 230. SAUDI ARABIA ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
TABLE 231. SAUDI ARABIA ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 232. SAUDI ARABIA ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 233. SOUTH AFRICA ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 234. SOUTH AFRICA ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 235. SOUTH AFRICA ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
TABLE 236. SOUTH AFRICA ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
TABLE 237. SOUTH AFRICA ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 238. SOUTH AFRICA ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 239. SPAIN ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 240. SPAIN ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 241. SPAIN ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
TABLE 242. SPAIN ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
TABLE 243. SPAIN ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 244. SPAIN ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 245. SWEDEN ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 246. SWEDEN ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 247. SWEDEN ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
TABLE 248. SWEDEN ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
TABLE 249. SWEDEN ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 250. SWEDEN ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 251. SWITZERLAND ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 252. SWITZERLAND ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 253. SWITZERLAND ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
TABLE 254. SWITZERLAND ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
TABLE 255. SWITZERLAND ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 256. SWITZERLAND ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 257. TURKEY ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 258. TURKEY ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 259. TURKEY ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
TABLE 260. TURKEY ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
TABLE 261. TURKEY ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 262. TURKEY ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 263. UNITED ARAB EMIRATES ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 264. UNITED ARAB EMIRATES ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 265. UNITED ARAB EMIRATES ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
TABLE 266. UNITED ARAB EMIRATES ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
TABLE 267. UNITED ARAB EMIRATES ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 268. UNITED ARAB EMIRATES ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 269. UNITED KINGDOM ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 270. UNITED KINGDOM ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 271. UNITED KINGDOM ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
TABLE 272. UNITED KINGDOM ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
TABLE 273. UNITED KINGDOM ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 274. UNITED KINGDOM ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 275. ANGIOEDEMA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023
TABLE 276. ANGIOEDEMA TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
TABLE 277. ANGIOEDEMA TREATMENT MARKET LICENSE & PRICING

Companies Mentioned

  • Adverum Biotechnologies, Inc.
  • AMBOSS GmbH
  • Apotex Corp.
  • Attune Pharmaceuticals, Inc.
  • BioCryst Pharmaceuticals, Inc.
  • Cipla USA Inc.
  • CSL Behring GmbH
  • Fresenius Kabi USA, LLC
  • Ionis Pharmaceuticals, Inc.
  • KalVista Pharmaceuticals, Inc.
  • Lecturio GmbH
  • Merck & Co., Inc.
  • Pharming Group N.V.
  • Sanofi-Aventis Groupe S.A.
  • Slayback Pharma LLC
  • Takeda Pharmaceutical Company Limited
  • Viropharma Biologics LLC

Methodology

Loading
LOADING...